Sol-Gel Technologies Share Holder Equity 2016-2023 | SLGL
Sol-Gel Technologies share holder equity from 2016 to 2023. Share holder equity can be defined as the sum of preferred and common equity items
Sol-Gel Technologies Annual Share Holder Equity
(Millions of US $) |
| 2023 |
$39 |
| 2022 |
$42 |
| 2021 |
$56 |
| 2020 |
$51 |
| 2019 |
$52 |
| 2018 |
$64 |
| 2017 |
$-53 |
| 2016 |
$-31 |
| 2015 |
$-12 |
Sol-Gel Technologies Quarterly Share Holder Equity
(Millions of US $) |
| 2023-12-31 |
$39 |
| 2023-09-30 |
$43 |
| 2023-06-30 |
$48 |
| 2023-03-31 |
$44 |
| 2022-12-31 |
$42 |
| 2022-09-30 |
$47 |
| 2022-06-30 |
$50 |
| 2022-03-31 |
$50 |
| 2021-12-31 |
$56 |
| 2021-09-30 |
$41 |
| 2021-06-30 |
$39 |
| 2021-03-31 |
$47 |
| 2020-12-31 |
$51 |
| 2020-09-30 |
$57 |
| 2020-06-30 |
$66 |
| 2020-03-31 |
$67 |
| 2019-12-31 |
$52 |
| 2019-09-30 |
$59 |
| 2019-06-30 |
$55 |
| 2019-03-31 |
$59 |
| 2018-06-30 |
$82 |
| 2018-03-31 |
$87 |
| 2017-12-31 |
|
| 2017-09-30 |
$-49 |
| 2017-06-30 |
$0 |
| 2016-12-31 |
$-31 |
| 2015-12-31 |
$-12 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.025B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
